Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

The Lilly Way

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.
May 2, 2010

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.

The Lilly Way

Lilly faces up to the new realities of the bio/pharmaceutical industry by embracing outsourcing.
May 1, 2010

Lilly faces up to the new realities of the bio/pharmaceutical industry by embracing outsourcing.

Time for a Model Upgrade

CMOs' business model has all of the flaws of the captive model it is meant to replace.
Apr 7, 2010

CMOs' business model has all of the flaws of the captive model it is meant to replace.

Time for a Model Upgrade

CMOs' business model has all of the flaws of the captive model it is meant to replace.
Mar 2, 2010

CMOs' business model has all of the flaws of the captive model it is meant to replace.

A Look Ahead for 2010

Some predictions for contract services in 2010.
Feb 3, 2010

Some predictions for contract services in 2010.

Squeezed for Cash

Big Pharma's efforts to reduce working capital will hurt CMOs for years to come.
Jan 6, 2010

Big Pharma's efforts to reduce working capital will hurt CMOs for years to come.

A Look Ahead for 2010

Some predictions for contract services in 2010.
Jan 2, 2010

Some predictions for contract services in 2010.

The year ahead

Some predictions about what's in store for contract services in 2010.
Jan 1, 2010

It's customary among columnists to begin a new year with some predictions about what's to come. We don't honour that custom every year, but with what the contract services industry went through in 2009, it seemed appropriate to share thoughts on what we expect for 2010.

Squeezed for Cash

Big Pharma's efforts to reduce working capital will hurt CMOs for years to come.
Dec 2, 2009

Big Pharma's efforts to reduce working capital will hurt CMOs for years to come.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
FindPharma Custom Search
Click here